secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001683168-24-007758
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma Q3 2024 revenues up 42% YoY; net loss widens 84% in quarter
------------------------------------------------------------------------------

- Q3 2024 gross revenues $8.44M, up 42% from $5.96M in Q3 2023; YTD revenues $25.28M, up 54%.
- Q3 net loss $(1.20M) compared to $(0.65M) in Q3 2023, a YoY increase of 84%.
- YTD net loss $(2.98M) vs $(3.26M) in prior year period, an improvement of 9%.
- Shareholders' equity grew 18% to $25.04M from $21.21M at Dec 31, 2023.
- Growth driven by new product launches and expanded marketing via Canadian subsidiary Nora Pharma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824007758/0001683168-24-007758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824007758/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-007758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer